{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:12Z","timestamp":1792153992455,"version":"4.4.0"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin (IL)-18 is a pleiotropic, pro-inflammatory cytokine involved in the regulation of innate and adaptive immune responses. IL-18 has attracted increasing attention as a key mediator in autoinflammatory diseases associated with the development of macrophage activation syndrome (MAS) including systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. In these diseases, dysregulation of inflammasome activity and overproduction of IL-18 might be associated with the development of MAS by inducing natural killer cell dysfunction. Serum IL-18 levels are high in patients with these diseases and therefore are useful for the diagnosis and monitoring of disease activity. In contrast, a recent study revealed the overproduction of IL-18 was present in cases of autoinflammation without susceptibility to MAS such as pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome. The pathogenic and causative roles of IL-18 remain unclear in these autoinflammatory diseases. Further investigations are necessary to clarify the role of IL-18 and its importance as a therapeutic target in the pathogenesis of autoinflammatory diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2022.951535","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:32:07Z","timestamp":1663853527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Masaki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1128\/iai.61.1.64-70.1993","article-title":"Purification of a factor which provides a costimulatory signal for gamma interferon production","volume":"61","author":"Nakamura","year":"1993","journal-title":"Infect Immun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.5.2256","article-title":"Gene expression, synthesis and secretion of IL-1b and IL-18 are differentially regulated in human blood mononuclear cells and mouse spleen cells","volume":"96","author":"Puren","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.159.1.298","article-title":"Production of IL-18 (IFNg\u2013inducing factor) messenger RNA and functional protein by murine keratinocytes","volume":"159","author":"Stoll","year":"1997","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s004410050895","article-title":"Immunohistochemical and immuno-electron-microscopic detection of interferon-gamma-inducing factor (\"interleukin-18\") in mouse intestinal epithelial cells","volume":"289","author":"Takeuchi","year":"1997","journal-title":"Cell Tissue Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12950-015-0089-9","article-title":"Interleukin-18 expression increases in response to neurovascular damage following soman-induced status epilepticus in rats","volume":"12","author":"Johnson","year":"2015","journal-title":"J Inflammation (Lond)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.048","article-title":"Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling","volume":"163","author":"Levy","year":"2015","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature22967","article-title":"Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells","volume":"546","author":"Zhu","year":"2017","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00148-9","article-title":"Cloning and expression of interleukin-18 binding protein","volume":"445","author":"Aizawa","year":"1999","journal-title":"FEBS Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.212519099","article-title":"A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity","volume":"99","author":"Bufler","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PloS Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.10389","article-title":"Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: Comment on the article by kawashima et al","volume":"46","author":"Maeno","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0474-0","article-title":"Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis","volume":"26","author":"Jelusi\u0107","year":"2007","journal-title":"Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmt007","article-title":"The imbalance of IL-18\/IL-18BP in patients with systemic juvenile idiopathic arthritis","volume":"45","author":"Chen","year":"2013","journal-title":"Acta Biochim Biophys Sin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab113","article-title":"A dysregulated interleukin-18-interferon-\u03b3-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis","volume":"60","author":"Hinze","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa299","article-title":"Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children","volume":"60","author":"Mizuta","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa634","article-title":"Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis","volume":"60","author":"Mizuta","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset still\u2019s disease: Comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol Orlando Fla"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-019-0053-z","article-title":"Comparative study of interleukin-18 (IL-18) serum levels in adult onset still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity","volume":"3","author":"Kudela","year":"2019","journal-title":"BMC Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset still's disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750114","article-title":"Usefulness of interleukin-18 as a diagnostic biomarker to differentiate adult-onset still's disease With\/Without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults","volume":"12","author":"Shiga","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.09.007","article-title":"Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency","volume":"65","author":"Wada","year":"2014","journal-title":"Cytokine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01236-2","article-title":"XIAP deficiency treatment consortium. A case of XIAP deficiency successfully managed with tadekinig Alfa(rhIL-18BP)","volume":"42","author":"Geerlinks","year":"2022","journal-title":"J Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12969-019-0328-3","article-title":"An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"17","author":"Arduini","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.41976","article-title":"Excess serum interleukin-18 distinguishes patients with pathogenic mutations in PSTPIP1","volume":"74","author":"Stone","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.7.3400","article-title":"IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and b cells: synergism with IL-18 for IFNgamma production","volume":"161","author":"Yoshimoto","year":"1998","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.12.2103","article-title":"Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation","volume":"187","author":"Munder","year":"1998","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3075","article-title":"The production of IFN-gamma by IL-12\/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4","volume":"166","author":"Schindler","year":"2001","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.9.5070","article-title":"IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response","volume":"162","author":"Hoshino","year":"1999","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/77811","article-title":"IL-18 induction of IgE: Dependence on CD4+ T cells, IL-4 and STAT6","volume":"1","author":"Yoshimoto","year":"2000","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.24.13962","article-title":"IL-18, although antiallergic when administered with IL-12, stimulates IL-4andhistamine release by basophils","volume":"96","author":"Yoshimoto","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.40099","article-title":"Proinflammatory cytokine environments can drive interleukin-17 overexpression by \u03b3\/\u03b4 T cells in systemic juvenile idiopathic arthritis","volume":"69","author":"Kessel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61029","article-title":"DC-Derived IL-18drives treg differentiation, murine helicobacter pylori-specific immune tolerance, and asthma protection","volume":"122","author":"Oertli","year":"2012","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2879","article-title":"A role for IL-18 in neutrophil activation","volume":"167","author":"Leung","year":"2001","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7317","article-title":"A proinflammatory role for IL-18 in rheumatoid arthritis","volume":"104","author":"Gracie","year":"1999","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.2.734","article-title":"IL-18 regulates IL-1beta-Dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1","volume":"97","author":"Vidal-Vanaclocha","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.157.9.3967","article-title":"IFN-gamma-inducing factor up-regulates fas ligand-mediated cytotoxic activity of murine natural killer cell clones","volume":"157","author":"Tsutsui","year":"1996","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01250","article-title":"Analysis of serum interleukin (IL)-1\u03b2 and IL-18 in systemic lupus erythematosus","volume":"9","author":"Mende","year":"2018","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ibd.20272","article-title":"Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease","volume":"14","author":"Leach","year":"2008","journal-title":"Inflammation Bowel Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: Some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.38615","article-title":"Review: Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132508","article-title":"Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis","volume":"5","author":"Henderson","year":"2020","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601342","article-title":"Alarmins: feel the stress","volume":"198","author":"Rider","year":"2017","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00391","article-title":"The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines","volume":"4","author":"Kim","year":"2013","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1912893","article-title":"Macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"44","author":"Shimizu","year":"2021","journal-title":"Immunol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"key":"B70","article-title":"The incidence of macrophage activation syndrome in children with rheumatic disorders","volume":"63","author":"Moradinejad","year":"2011","journal-title":"Minerva Pediatr"},{"key":"B71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MD.0b013e3181caf100","article-title":"Reactive hemophagocytic syndrome in adult-onset still disease: clinical features and long-term outcome: A case-control study of 8 patients","volume":"89","author":"Hot","year":"2010","journal-title":"Med (Baltimore)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken342","article-title":"Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: Analysis of 30 cases","volume":"47","author":"Fukaya","year":"2008","journal-title":"Rheumatol (Oxford)"},{"key":"B73","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141091","article-title":"An inherited mutation in NLRC4 causes autoinflammation in human and mice","volume":"211","author":"Kitamura","year":"2014","journal-title":"J Exp Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nature05257","article-title":"XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome","volume":"444","author":"Rigaud","year":"2006","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275909","article-title":"X-Linked lymphoproliferative syndromes: Brothers or distant cousins","volume":"116","author":"Filipovich","year":"2010","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2012.03683.x","article-title":"SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis","volume":"54","author":"Yang","year":"2012","journal-title":"Pediatr Int"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<884::AID-ANR145>3.0.CO;2-4","article-title":"A novel role for interleukin-18 in human natural killer cell death: High serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases","volume":"44","author":"Shibatomi","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"de Jager","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13679","article-title":"Transient natural killer cell dysfunction associated with interleukin-18 overproduction in systemic juvenile idiopathic arthritis","volume":"60","author":"Takakura","year":"2018","journal-title":"Pediatr Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11426","article-title":"Impaired interleukin-18 signaling in natural killer cells from patients with systemic juvenile idiopathic arthritis","volume":"4","author":"Ohya","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.07.005","article-title":"Macrophage activation syndrome in neonates born to mothers with adult-onset still's disease: Perinatal effect of maternal IL-18","volume":"207","author":"Shimizu","year":"2019","journal-title":"Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.03.004","article-title":"Transient impairment of NK cell function in an infant born to a mother with adult-onset still's disease: Perinatal effect of maternal IL-18","volume":"143","author":"Shimizu","year":"2012","journal-title":"Clin Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190669","article-title":"Inherited IL-18BP deficiency in human fulminant viral hepatitis","volume":"216","author":"Belkaya","year":"2019","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00239","article-title":"Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein","volume":"3","author":"Chiossone","year":"2012","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.11.6829","article-title":"IL-18, a novel immunoregulatory cytokine, is up-regulated in crohn's disease: Expression and localization in intestinal mucosal cells","volume":"162","author":"Pizarro","year":"1999","journal-title":"J Immunol"},{"key":"B90","article-title":"Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells","volume":"28","author":"Tanaka","year":"2001","journal-title":"J Rheumatol"},{"key":"B91","article-title":"Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions","volume":"15","author":"Companjen","year":"2004","journal-title":"Eur Cytokine Netw"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.11.2918.2918","article-title":"Hypercytokinemia in familial hemophagocytic lymphohistiocytosis","volume":"78","author":"Henter","year":"1991","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.4100","article-title":"Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis","volume":"89","author":"Osugi","year":"1997","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.11.046","article-title":"Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children","volume":"160","author":"Xu","year":"2012","journal-title":"J Pediatr"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu524","article-title":"Inflammatory gene expression profile and defective interferon-\u03b3 and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062447","article-title":"Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: A mouse model of type 3 familial hemophagocytic lymphohistiocytosis","volume":"204","author":"Crozat","year":"2007","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131193098","article-title":"Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A\/DSHP\/SAP","volume":"98","author":"Czar","year":"2001","journal-title":"Pro Natl Acad Sci USA"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441139","article-title":"Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease","volume":"121","author":"Kogl","year":"2013","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.200900009","article-title":"Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice","volume":"1","author":"Pachlopnik Schmid","year":"2009","journal-title":"EMBO Mol Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.024","article-title":"Mutations at the c-terminus of CDC42 cause distinct hematopoietic and autoinflammatory disorders","volume":"150","author":"Coppola","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37275","article-title":"Macrothrombocytopenia and developmental delay with a de novo CDC42 mutation: yet another locus for thrombocytopenia and developmental delay","author":"Takenouchi","year":"2015","journal-title":"Am J Med Genet A"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37526","article-title":"Further evidence of a mutation in CDC42 as a cause of a recognizable syndromic form of thrombocytopenia","author":"Takenouchi","year":"2016","journal-title":"Am J Med Genet A"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.12.015","article-title":"Functional dysregulation of CDC42 causes diverse developmental phenotypes","volume":"102","author":"Martinelli","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/genes12020294","article-title":"Pancytopenia, recurrent infection, poor wound healing, heterotopia of the brain probably associated with a candidate novel de novo CDC42 gene defect: expanding the molecular and phenotypic spectrum","volume":"12","author":"Asiri","year":"2021","journal-title":"Genes"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00318","article-title":"A novel CDC42 mutation in an 11-year old child manifesting as syndromic immunodeficiency, autoinflammation, hemophagocytic lymphohistiocytosis, and malignancy: a case report","volume":"11","author":"Szczawinska-Poplonyk","year":"2021","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)00571-6","article-title":"Cdc42 is required for PIP(2)-induced actin polymerization and early development but not for cell viability","volume":"10","author":"Chen","year":"2000","journal-title":"Curr Biol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/jem.20161228","article-title":"Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1","volume":"214","author":"Standing","year":"2017","journal-title":"J Exp Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-706028","article-title":"Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency","volume":"128","author":"Kuhns","year":"2016","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleosidephosphorylase deficiency in a child with severely defective T-cell immunity and normal b-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2006.07.008","article-title":"Progressive multifocal leukoencephalopathy in purine nucleoside phosphorylase deficiency","volume":"29","author":"Parvaneh","year":"2007","journal-title":"Brain Dev"},{"key":"B116","first-page":"45","article-title":"Purine nucleoside phosphorylase deficiency","volume":"3","author":"Markert","year":"1991","journal-title":"Immunodefic Rev"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.8.961","article-title":"Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder","volume":"11","author":"Wise","year":"2002","journal-title":"Hum Mol Genet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/adc.81.2.179","article-title":"High IL-18 (interferon-gamma inducing factor) concentration in a purine nucleoside phosphorylase deficient patient","volume":"81","author":"Yamamoto","year":"1999","journal-title":"Arch Dis Child"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/art.27521","article-title":"Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome","volume":"62","author":"Cortesio","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10514","article-title":"Pyrin-PSTPIP1 colocalises at the leading edge during cell migration","volume":"39","author":"Akkaya-Ulum","year":"2015","journal-title":"Cell Biol Int"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14696","article-title":"Role of E148Q in familial Mediterranean fever with an exon 10 mutation in MEFV","volume":"64","author":"Miyashita","year":"2022","journal-title":"Pediatr Int"},{"key":"B122","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800468","article-title":"Insufficient IL-10 production as a mechanism underlying thee pathogenesis of systemic juvenile idiopathic arthritis","volume":"201","author":"Imbrechts","year":"2018","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214496","article-title":"Prolonged treatment with tadekinig alfa in adult-onset still's disease","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.951535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T02:25:50Z","timestamp":1676859950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.951535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":127,"alternative-id":["10.3389\/fimmu.2022.951535"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.951535","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"article-number":"951535"}}